ROCURONIUM-HAMELN (Hameln Pharma Pty Ltd)
Product name
ROCURONIUM-HAMELN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
52 (255 working days)
Active ingredients
rocuronium bromide
Registration type
New generic medicine
Indication
Rocuronium is indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, and paediatric patients from term newborn infants to adolescents.
In adults, rocuronium is also indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated.
In adults, rocuronium is also indicated as an adjunct in the intensive care unit (ICU) to facilitate mechanical ventilation.